Inclusion Criteria:

          -  1. Age from 18 to 70 years with estimated life expectancy >3 months.

          -  2. Histopathological confirmed locally advanced or metastatic systematically
             pretreated epidermal growth factor receptor (EGFR) / anaplastic lymphoma kinase (ALK)
             / c-ros oncogene 1 receptor kinase (ROS1) /BRAF negative non-small cell lung cancer
             (adenocarcinoma or squamous cell carcinoma), pancreatic adenocarcinoma,
             cholangiocarcinoma, gastrointestinal adenocarcinoma, triple-negative breast cancer and
             relapsed/refractory B-cell lymphoma (All enrolled subjects with above solid carcinoma
             are required to have received at least first-line systematic therapy and subjects with
             R/R B-cell lymphoma need a history of at least two lines of previous treatment; For
             solid carcinoma subjects enrolled in phase Ⅱ period, their previous treatment lines
             are limited to no more than four lines; Besides previously treated subjects, subjects
             with initially diagnosed pancreatic adenocarcinoma or cholangiocarcinoma are also
             eligible for enrollment in phase Ⅱ period).

          -  3. Have at least one measurable target lesion, determined by the site study team based
             on RECIST 1.1 and immune related RECIST.

          -  4. Fresh tumor samples or formalin-fixed paraffin embedded tumor archival samples
             within 3 months are necessary; Fresh tumor samples are preferred. Subjects are willing
             to accept tumor re-biopsy in the process of this study.

          -  5. Previous treatment must be completed for more than 4 weeks prior to the enrollment
             of this study, and subjects have recovered to <= grade 1 toxicity.

          -  6. Have an Eastern Cooperative Oncology Group performance status (ECOG) of 0 or 1 at
             the time of enrollment.

          -  7. Have adequate organ function, as defined in the table below, which should be
             confirmed within 2 weeks prior to the first dose of study drugs.

               -  Leukocytes greater than or equal to 3.0 ×10^9/L.

               -  Absolute neutrophil counts greater than or equal to 1.0 ×10^9/L.

               -  Platelets greater than or equal to 100 ×10^9/L.

               -  Hemoglobin greater than or equal to 90 g/L.

               -  Total bilirubin less than or equal to 2 x ULN.

               -  Serum albumin should be no less than 30 g/L.

               -  Alanine aminotransferase or Aspartate aminotransferase less than 2 x Upper Limit
                  of Normal (ULN).

               -  Measured creatinine clearance ≥ 60 mL per min.

          -  8. Previous treatment with anti-PD-1/PD-L1 antibodies or cytotoxic T lymphocyte
             associated antigen 4 (CTLA-4) inhibitors are allowed.

          -  9. Ability to understand and sign a written informed consent document.

          -  10.Women of child-bearing potential must agree to use adequate contraception (hormonal
             or barrier method of birth control; abstinence) prior to study entry, and up to 90
             days after the last dose of the drug.

        Exclusion Criteria:

          -  1. Active, known or suspected autoimmune diseases.

          -  2. Known brain metastases or active central nervous system (CNS). Subjects with CNS
             metastases who were treated with radiotherapy for at least 3 months prior to
             enrollment, have no central nervous symptoms and are off corticosteroids, are eligible
             for enrollment, but require a brain MRI screening.

          -  3. Subjects are being treated with either corticosteroids (>10 mg daily prednisone
             equivalent) or other immunosuppressive medications within 14 days of enrollment.

          -  4. History of severe hypersensitive reactions to other monoclonal antibodies.

          -  5. History of allergy or intolerance to study drug components.

          -  6. Substance abuse, medical, psychological or social conditions that may interfere
             with the patient's participation in the study or evaluation of the study results.

          -  7. History or concurrent condition of interstitial lung disease of any grade or
             severely impaired pulmonary function.

          -  8. Uncontrolled intercurrent illness, including ongoing or active systemic infection,
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
             (excluding insignificant sinus bradycardia and sinus tachycardia) or psychiatric
             illness/social situations and any other illness that would limit compliance with study
             requirements and jeopardize the safety of the patient.

          -  9. History of human immunodeficiency virus (HIV) infection or acquired
             immunodeficiency syndrome (AIDS).

          -  10. Pregnant or breast-feeding. Women of childbearing potential must have a pregnancy
             test performed within 7 days before the enrollment, and a negative result must be
             documented.

          -  11. Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for
             curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial
             bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades
             lamina propria)].

          -  12. Vaccination within 30 days of study enrollment.

          -  13. Active bleeding or known hemorrhagic tendency.

          -  14. Subjects with unhealed surgical wounds for more than 30 days.

          -  15. Being participating any other trials or withdraw within 4 weeks.